PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in ...
PDS Biotechnology announces circulating tumor DNA results for Versamune HPV
PDS Biotechnology (PDSB) announced the publication of circulating tumor DNA results for its lead immunotherapy candidate, Versamune HPV, in ...
Morningstar2d
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune ...
Morningstar6d
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination ...
Yahoo Finance6d
PDS Biotechnology Corporation (PDSB)
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV ...
PDSB stock touches 52-week low at $1.3 amid market challenges
PDS Biotechnology Corporation (NASDAQ:PDSB) stock has reached a 52-week low, trading at $1.3, as investors navigate a ...